Veliparib

Generic Name: Veliparib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Stage IIIC Breast Cancer AJCC v7
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer AJCC v7
Locally Advanced Unresectable Breast Carcinoma
Metastatic Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Veliparib

First Posted Date: 2011-05-11

Last Posted Date: 2024-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT01351909

Locations: 🇺🇸
Montefiore Medical Center-Einstein Campus, Bronx, New York, United States
🇺🇸
Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States
🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States

and more 2 locations

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Phase 1

Completed

Conditions: Anaplastic Large Cell Lymphoma
Chronic Lymphocytic Leukemia
Adult B Acute Lymphoblastic Leukemia
Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Adult Solid Neoplasm
Lymphomatous Involvement of Non-Cutaneous Extranodal Site
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Angioimmunoblastic T-Cell Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Other: Pharmacological Study
Biological: Rituximab
Drug: Veliparib

First Posted Date: 2011-03-31

Last Posted Date: 2019-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT01326702

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
Stage III Bladder Cancer
Stage III Pancreatic Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Bladder Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: veliparib
Other: diagnostic laboratory biomarker analysis
Other: pharmacological study
Drug: cisplatin

First Posted Date: 2011-01-25

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT01282333

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Phase 1

Completed

Conditions: Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Recurrent Cervical Carcinoma
Stage IVB Cervical Cancer AJCC v6 and v7

Interventions: Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Veliparib

First Posted Date: 2011-01-24

Last Posted Date: 2019-07-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT01281852

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States

and more 22 locations

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Adult Solid Neoplasm
Estrogen Receptor Negative
Estrogen Receptor Positive
HER2/Neu Negative
Male Breast Carcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2011-01-21

Last Posted Date: 2015-05-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT01281150

Locations: 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Squamous Cell Carcinoma
Stage III Cervical Cancer
Cervical Small Cell Carcinoma
Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
Recurrent Cervical Carcinoma
Stage IVA Cervical Cancer
Stage IVB Cervical Cancer

Interventions: Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Biological: Pegfilgrastim
Drug: Topotecan Hydrochloride
Drug: Veliparib

First Posted Date: 2010-12-24

Last Posted Date: 2019-08-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT01266447

Locations: 🇺🇸
Cooper Hospital University Medical Center, Camden, New Jersey, United States
🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 75 locations

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Adult Solid Neoplasm
Peritoneal Carcinomatosis
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Veliparib

First Posted Date: 2010-12-21

Last Posted Date: 2017-11-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT01264432

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Breast Carcinoma
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Triple-Negative Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Other: Fluorothymidine F-18
Procedure: Positron Emission Tomography
Drug: Veliparib

First Posted Date: 2010-12-02

Last Posted Date: 2024-11-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT01251874

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
🇺🇸
Montefiore Medical Center-Einstein Campus, Bronx, New York, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Adenocarcinoma of the Pancreas
Adenocarcinoma of the Stomach
BRCA1 Mutation Carrier
BRCA2 Mutation Carrier
Ovarian Mucinous Cystadenocarcinoma
Recurrent Breast Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IIIA Breast Cancer
Recurrent Gastric Cancer

Interventions: Drug: veliparib
Drug: capecitabine
Drug: oxaliplatin
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2010-11-03

Last Posted Date: 2014-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT01233505

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: veliparib

First Posted Date: 2010-09-10

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 27

Registration Number: NCT01199224

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy